Jane Street Group LLC Cuts Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Jane Street Group LLC reduced its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 86.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 69,397 shares of the specialty pharmaceutical company's stock after selling 450,311 shares during the period. Jane Street Group LLC owned about 0.14% of KalVista Pharmaceuticals worth $588,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of KALV. PDT Partners LLC boosted its stake in shares of KalVista Pharmaceuticals by 56.8% in the fourth quarter. PDT Partners LLC now owns 35,201 shares of the specialty pharmaceutical company's stock worth $298,000 after acquiring an additional 12,747 shares during the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter worth approximately $44,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter worth approximately $680,000. Nebula Research & Development LLC acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter worth approximately $98,000. Finally, Syon Capital LLC acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter worth approximately $93,000.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,776 shares of KalVista Pharmaceuticals stock in a transaction on Monday, May 19th. The stock was sold at an average price of $11.84, for a total value of $32,867.84. Following the sale, the insider now owns 106,611 shares in the company, valued at $1,262,274.24. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Venrock Healthcare Capital Par bought 25,000 shares of KalVista Pharmaceuticals stock in a transaction on Wednesday, April 9th. The stock was acquired at an average price of $9.42 per share, for a total transaction of $235,500.00. Following the transaction, the insider now directly owns 5,303,985 shares of the company's stock, valued at approximately $49,963,538.70. This trade represents a 0.47% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 15,399 shares of company stock valued at $182,054. Insiders own 10.50% of the company's stock.

KalVista Pharmaceuticals Trading Down 1.1%

NASDAQ KALV traded down $0.13 on Friday, reaching $11.76. 703,041 shares of the company were exchanged, compared to its average volume of 426,299. The business's fifty day moving average price is $11.90 and its 200 day moving average price is $10.47. The stock has a market capitalization of $584.66 million, a P/E ratio of -3.23 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $15.50.

Analyst Upgrades and Downgrades

KALV has been the topic of a number of research analyst reports. Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a research note on Friday, January 31st. JMP Securities initiated coverage on KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an "outperform" rating and a $19.00 price target on the stock. Jones Trading reaffirmed a "buy" rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Finally, Needham & Company LLC reissued a "buy" rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $24.83.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).